# Amphastar Pharmaceuticals, Inc.: financial statements, quarterly

AMPH · Nasdaq · CIK 1297184 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/amph.md) · [Financials](/companies/amph/financials.md) · [Filings](/companies/amph/filings.md) · [Insiders](/companies/amph/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/amph/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [181](/filings/0001297184-24-000058.md) | [178 d](/filings/0001297184-26-000009.md) | [172](/filings/0001297184-25-000029.md) | [182](/filings/0001297184-25-000050.md) | [191](/filings/0001297184-25-000064.md) | [187 d](/filings/0001297184-26-000009.md) | [171](/filings/0001297184-26-000033.md) | [174](/filings/0001297184-26-000047.md) | [192](/filings/0001297184-25-000064.md) | [183 d](/filings/0001297184-26-000009.md) | [171](/filings/0001297184-26-000033.md) | [184](/filings/0001297184-26-000047.md) |
| Cost of revenue | $m | [72.2](/filings/0001297184-24-000058.md) | [82.0 d](/filings/0001297184-26-000009.md) | [81.7](/filings/0001297184-25-000029.md) | [87.2](/filings/0001297184-25-000050.md) | [89.3](/filings/0001297184-25-000064.md) | [99.9 d](/filings/0001297184-26-000009.md) | [85.3](/filings/0001297184-26-000033.md) | [87.9](/filings/0001297184-26-000047.md) | [93.2](/filings/0001297184-25-000064.md) | [97.4 d](/filings/0001297184-26-000009.md) | [101](/filings/0001297184-26-000033.md) | [90.4](/filings/0001297184-26-000047.md) |
| Gross profit | $m | [108](/filings/0001297184-24-000058.md) | [96.1 d](/filings/0001297184-26-000009.md) | [90.1](/filings/0001297184-25-000029.md) | [95.2](/filings/0001297184-25-000050.md) | [102](/filings/0001297184-25-000064.md) | [86.6 d](/filings/0001297184-26-000009.md) | [85.3](/filings/0001297184-26-000033.md) | [86.5](/filings/0001297184-26-000047.md) | [98.6](/filings/0001297184-25-000064.md) | [85.7 d](/filings/0001297184-26-000009.md) | [70.3](/filings/0001297184-26-000033.md) | [93.5](/filings/0001297184-26-000047.md) |
| Research and development | $m | [16.7](/filings/0001297184-24-000058.md) | [20.4 d](/filings/0001297184-26-000009.md) | [17.0](/filings/0001297184-25-000029.md) | [17.7](/filings/0001297184-25-000050.md) | [21.1](/filings/0001297184-25-000064.md) | [18.1 d](/filings/0001297184-26-000009.md) | [20.1](/filings/0001297184-26-000033.md) | [20.1](/filings/0001297184-26-000047.md) | [22.4](/filings/0001297184-25-000064.md) | [23.3 d](/filings/0001297184-26-000009.md) | [26.7](/filings/0001297184-26-000033.md) | [22.2](/filings/0001297184-26-000047.md) |
| Operating income | $m | [72.7](/filings/0001297184-24-000058.md) | [54.0 d](/filings/0001297184-26-000009.md) | [48.0](/filings/0001297184-25-000029.md) | [55.2](/filings/0001297184-25-000050.md) | [57.0](/filings/0001297184-25-000064.md) | [45.1 d](/filings/0001297184-26-000009.md) | [37.3](/filings/0001297184-26-000033.md) | [42.2](/filings/0001297184-26-000047.md) | [25.3](/filings/0001297184-25-000064.md) | [35.6 d](/filings/0001297184-26-000009.md) | [13.6](/filings/0001297184-26-000033.md) | [39.7](/filings/0001297184-26-000047.md) |
| Interest expense | $m | [13.7](/filings/0001297184-23-000082.md) | [9.5 d](/filings/0001297184-24-000009.md) | [8.6](/filings/0001297184-24-000037.md) | [8.6](/filings/0001297184-25-000050.md) | [6.7](/filings/0001297184-25-000064.md) | [6.4 d](/filings/0001297184-26-000009.md) | [6.3](/filings/0001297184-26-000033.md) | [6.3](/filings/0001297184-26-000047.md) | [6.3](/filings/0001297184-25-000064.md) | [6.6 d](/filings/0001297184-26-000009.md) | [6.6](/filings/0001297184-26-000033.md) | [6.7](/filings/0001297184-26-000047.md) |
| Income tax | $m | [14.0](/filings/0001297184-24-000058.md) | [4.7 d](/filings/0001297184-26-000009.md) | [4.1](/filings/0001297184-25-000029.md) | [12.3](/filings/0001297184-25-000050.md) | [7.3](/filings/0001297184-25-000064.md) | [6.0 d](/filings/0001297184-26-000009.md) | [5.6](/filings/0001297184-26-000033.md) | [8.3](/filings/0001297184-26-000047.md) | [4.2](/filings/0001297184-25-000064.md) | [7.5 d](/filings/0001297184-26-000009.md) | [3.6](/filings/0001297184-26-000033.md) | [8.2](/filings/0001297184-26-000047.md) |
| Net income | $m | [49.2](/filings/0001297184-24-000058.md) | [36.2 d](/filings/0001297184-26-000009.md) | [43.2](/filings/0001297184-25-000064.md) | [37.9](/filings/0001297184-25-000064.md) | [40.4](/filings/0001297184-25-000064.md) | [38.0 d](/filings/0001297184-26-000009.md) | [25.3](/filings/0001297184-26-000047.md) | [31.0](/filings/0001297184-26-000047.md) | [17.4](/filings/0001297184-25-000064.md) | [24.4 d](/filings/0001297184-26-000009.md) | [6.4](/filings/0001297184-26-000047.md) | [30.3](/filings/0001297184-26-000047.md) |
| Diluted EPS | $ per share | [0.91](/filings/0001297184-24-000058.md) | not reported | [0.81](/filings/0001297184-25-000029.md) | [0.73](/filings/0001297184-25-000050.md) | [0.78](/filings/0001297184-25-000064.md) | not reported | [0.51](/filings/0001297184-26-000033.md) | [0.64](/filings/0001297184-26-000047.md) | [0.37](/filings/0001297184-25-000064.md) | not reported | [0.14](/filings/0001297184-26-000033.md) | [0.67](/filings/0001297184-26-000047.md) |
| Basic EPS | $ per share | [1.01](/filings/0001297184-24-000058.md) | not reported | [0.90](/filings/0001297184-25-000029.md) | [0.77](/filings/0001297184-25-000050.md) | [0.83](/filings/0001297184-25-000064.md) | not reported | [0.53](/filings/0001297184-26-000033.md) | [0.66](/filings/0001297184-26-000047.md) | [0.38](/filings/0001297184-25-000064.md) | not reported | [0.14](/filings/0001297184-26-000033.md) | [0.69](/filings/0001297184-26-000047.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [267](/filings/0001297184-23-000082.md) | [144](/filings/0001297184-25-000008.md) | [201](/filings/0001297184-24-000037.md) | [190](/filings/0001297184-24-000048.md) | [192](/filings/0001297184-24-000058.md) | [152](/filings/0001297184-26-000009.md) | [183](/filings/0001297184-25-000029.md) | [188](/filings/0001297184-25-000050.md) | [216](/filings/0001297184-25-000064.md) | [170](/filings/0001297184-26-000047.md) | [171](/filings/0001297184-26-000033.md) | [224](/filings/0001297184-26-000047.md) |
| Current assets | $m | [543](/filings/0001297184-23-000082.md) | [490](/filings/0001297184-25-000008.md) | [555](/filings/0001297184-24-000037.md) | [483](/filings/0001297184-24-000048.md) | [546](/filings/0001297184-24-000058.md) | [534](/filings/0001297184-26-000009.md) | [588](/filings/0001297184-25-000029.md) | [581](/filings/0001297184-25-000050.md) | [639](/filings/0001297184-25-000064.md) | [636](/filings/0001297184-26-000047.md) | [634](/filings/0001297184-26-000033.md) | [631](/filings/0001297184-26-000047.md) |
| Total assets | $m | [1,545](/filings/0001297184-23-000082.md) | [1,513](/filings/0001297184-25-000008.md) | [1,574](/filings/0001297184-24-000037.md) | [1,492](/filings/0001297184-24-000048.md) | [1,545](/filings/0001297184-24-000058.md) | [1,577](/filings/0001297184-26-000009.md) | [1,626](/filings/0001297184-25-000029.md) | [1,615](/filings/0001297184-25-000050.md) | [1,666](/filings/0001297184-25-000064.md) | [1,629](/filings/0001297184-26-000047.md) | [1,648](/filings/0001297184-26-000033.md) | [1,744](/filings/0001297184-26-000047.md) |
| Current liabilities | $m | [258](/filings/0001297184-23-000082.md) | [225](/filings/0001297184-25-000008.md) | [255](/filings/0001297184-24-000037.md) | [137](/filings/0001297184-24-000048.md) | [159](/filings/0001297184-24-000058.md) | [174](/filings/0001297184-26-000009.md) | [199](/filings/0001297184-25-000029.md) | [176](/filings/0001297184-25-000050.md) | [205](/filings/0001297184-25-000064.md) | [158](/filings/0001297184-26-000047.md) | [164](/filings/0001297184-26-000033.md) | [263](/filings/0001297184-26-000047.md) |
| Total liabilities | $m | [949](/filings/0001297184-23-000082.md) | [873](/filings/0001297184-25-000008.md) | [902](/filings/0001297184-24-000037.md) | [778](/filings/0001297184-24-000048.md) | [818](/filings/0001297184-24-000058.md) | [845](/filings/0001297184-26-000009.md) | [875](/filings/0001297184-25-000029.md) | [858](/filings/0001297184-25-000050.md) | [889](/filings/0001297184-25-000064.md) | [840](/filings/0001297184-26-000047.md) | [875](/filings/0001297184-26-000033.md) | [976](/filings/0001297184-26-000047.md) |
| Long-term debt | $m | [653](/filings/0001297184-23-000082.md) | [603](/filings/0001297184-24-000009.md) | not reported | not reported | not reported | [614](/filings/0001297184-25-000008.md) | not reported | not reported | not reported | [620](/filings/0001297184-26-000009.md) | not reported | not reported |
| Shareholders' equity | $m | [595](/filings/0001297184-24-000058.md) | [639](/filings/0001297184-26-000009.md) | [672](/filings/0001297184-25-000064.md) | [713](/filings/0001297184-25-000064.md) | [728](/filings/0001297184-25-000064.md) | [732](/filings/0001297184-26-000047.md) | [751](/filings/0001297184-26-000047.md) | [757](/filings/0001297184-26-000047.md) | [777](/filings/0001297184-25-000064.md) | [789](/filings/0001297184-26-000047.md) | [773](/filings/0001297184-26-000047.md) | [768](/filings/0001297184-26-000047.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Shareholders' equity: us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [64.3 d](/filings/0001297184-24-000058.md) | [23.9 d](/filings/0001297184-26-000009.md) | [55.3](/filings/0001297184-25-000029.md) | [69.1 d](/filings/0001297184-25-000050.md) | [60.0 d](/filings/0001297184-25-000064.md) | [29.0 d](/filings/0001297184-26-000009.md) | [35.1](/filings/0001297184-26-000033.md) | [35.6 d](/filings/0001297184-26-000047.md) | [52.6 d](/filings/0001297184-25-000064.md) | [32.9 d](/filings/0001297184-26-000009.md) | [47.8](/filings/0001297184-26-000033.md) | [51.3 d](/filings/0001297184-26-000047.md) |
| Capital expenditure | $m | [10.2 d](/filings/0001297184-24-000058.md) | [9.4 d](/filings/0001297184-26-000009.md) | [8.8](/filings/0001297184-25-000029.md) | [6.0 d](/filings/0001297184-25-000050.md) | [13.8 d](/filings/0001297184-25-000064.md) | [12.4 d](/filings/0001297184-26-000009.md) | [10.7](/filings/0001297184-26-000033.md) | [10.6 d](/filings/0001297184-26-000047.md) | [5.3 d](/filings/0001297184-25-000064.md) | [8.3 d](/filings/0001297184-26-000009.md) | [9.5](/filings/0001297184-26-000033.md) | [8.6 d](/filings/0001297184-26-000047.md) |
| Share repurchases | $m | [50.0 d](/filings/0001297184-24-000058.md) | [0.0 d](/filings/0001297184-26-000009.md) | not reported | not reported | [35.0 d](/filings/0001297184-25-000064.md) | [42.0 d](/filings/0001297184-26-000009.md) | [11.0](/filings/0001297184-26-000033.md) | [39.2 d](/filings/0001297184-26-000047.md) | [4.9 d](/filings/0001297184-25-000064.md) | [20.5 d](/filings/0001297184-26-000009.md) | [29.5](/filings/0001297184-26-000033.md) | [45.2 d](/filings/0001297184-26-000047.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [52.8](/filings/0001297184-23-000082.md) | [52.0](/filings/0001297184-24-000037.md) | [53.1](/filings/0001297184-24-000048.md) | [53.9](/filings/0001297184-24-000058.md) | [53.0](/filings/0001297184-25-000029.md) | [52.0](/filings/0001297184-25-000050.md) | [51.9](/filings/0001297184-25-000064.md) | [49.9](/filings/0001297184-26-000033.md) | [48.1](/filings/0001297184-26-000047.md) | [47.7](/filings/0001297184-25-000064.md) | [46.5](/filings/0001297184-26-000033.md) | [44.2](/filings/0001297184-26-000047.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 42,537,944 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001297184-26-000047.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:36 ET. No prices; not investment advice.